Document Detail

Sulpiride-induced tardive dyskinesia in a person with Gilles de la Tourette syndrome.
MedLine Citation:
PMID:  22290844     Owner:  NLM     Status:  In-Data-Review    
A 48 year old man who had never been treated with any other major tranquilliser developed tardive dyskinesia (TD) while taking sulpiride for Gilles de la Tourette syndrome (GTS). To our knowledge, this is the first report of TD complicating the use of sulpiride in the treatment of GTS.
V Eapen; C L Katona; T R Barnes; M M Robertson
Related Documents :
20535004 - Late onset purple toe syndrome with warfarin successfully treated with fondaparinux.
19396834 - Late-onset lennox-gastaut syndrome in a patient with 15q11.2-q13.1 duplication.
24668664 - Combined folate gene mthfd and tc polymorphisms as maternal risk factors for down syndr...
25372014 - A novel variation of gdf3 in chinese han children with a broad phenotypic spectrum of n...
21789664 - Deficiency of interleukin-1-receptor antagonist syndrome: a rare auto-inflammatory cond...
3517824 - Scimitar syndrome in neonates: report of four cases and review of the literature.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of psychopharmacology (Oxford, England)     Volume:  7     ISSN:  0269-8811     ISO Abbreviation:  J. Psychopharmacol. (Oxford)     Publication Date:  1993 Jan 
Date Detail:
Created Date:  2012-01-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907828     Medline TA:  J Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  290-2     Citation Subset:  -    
Department of Psychiatry, University College London Medical School, Wolfson Building, Middlesex Hospital, Riding House Street, London W1N 8AA, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxi...
Next Document:  Co-existence of panic disorder and sleep paralysis.